Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 26

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part II, Item 2
Chunk 26
---
 twenty prior trading days including the day upon which a Notice of Conversion
is received by the Company.

The
Note was issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “ Act”). No underwriters were
retained to serve as placement agents for the sale. The Note sold directly through our management. No commission or other consideration
was paid in connection with the sale of the Note. There was no advertisement or general solicitation made in connection with this Offer
and Sale of the Note. A legend was placed on the Note that evidences the Note has not been registered under the Act and setting forth
or referring to the restrictions on transferability and sale of the Note and the shares into which the Note may be converted.

On
August 1, 2025 the Company issued 1,000,000 common shares (“ Shares”) in satisfaction of $32,040 of accrued interest on convertible
indebtedness.

The
Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “ Act”). No underwriters were
retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration
was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer
and Sale of Shares.

On
August 1, 2025, the Company issued 1,000,000 common shares in satisfaction of $34,020 of accrued interest.

The
Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “ Act”). No underwriters were
retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration
was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer
and Sale of Shares.

  26  

On
August 5, 2025 the Company entered into a securities purchase agreement (the “ Purchase Agreement”) with Labrys Fund II LP
(“ Labrys”), pursuant to which Labrys purchased a 6% convertible promissory Note (the “ Note”) from the Company
in the principal amount of $100,000 of which $15,000 was retained by Labrys through an Original Issue Discount. The Note is due